title: Dysfunction of purinergic regulation of sympathetic neurotransmission in SHR/NDmcr-cp (SHR-cp) rat.
abstract: 1. The effect of 2-chloroadenosine (2CA), a P1 receptor agonist and beta,gamma-methylene ATP (betagamma mATP), a P2 receptor agonist, on the overflow of endogenous noradrenaline (NE) and the contractile response were examined in the electrically field-stimulated (EFS) (1 Hz) caudal artery obtained from Wistar-Kyoto (WKY) and SHR/NDmcr-cp (SHR-cp) rats. 2. Both 2CA and betagamma mATP reduced the EFS-evoked release of NE from the arteries of WKY. Also, 2CA significantly reduced the EFS-evoked contractile response in WKY, while it had no effect at all in SHR-cp. Betagamma mATP significantly reduced the EFS-evoked contractile response in both WKY and SHR-cp. Both 2CA and betagamma mATP did not affect the contractile response induced by NE at 1 micromol/L. 3. These results indicate that in the caudal arteries of SHR-cp, the P2 agonist but not the P1 agonist is functional in the prejunctional inhibitory regulation of adrenergic neurotransmission. This P1 dysfunction may play a role in the sympathetic hyperinnervation in metabolic syndrome.
authors.affiliation: First Department of Pharmacology, School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, Nobeoka, Miyazaki, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Tanaka
authors.forename: Namie
authors.initials: N
authors.lastname: Nejime
authors.forename: Satomi
authors.initials: S
authors.lastname: Kagota
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kubota
authors.forename: Kazuki
authors.initials: K
authors.lastname: Nakamura
authors.forename: Masaru
authors.initials: M
authors.lastname: Kunitomo
authors.forename: Michio
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Yamamoto
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Shinozuka
mesh_terms: D015762:2-Chloroadenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D004558:Electric Stimulation; D066298:In Vitro Techniques; D008297:Male; D024821:Metabolic Syndrome / Q000503:physiopathology; D009638:Norepinephrine / Q000502:physiology; D058906:Purinergic P1 Receptor Agonists; D058910:Purinergic P2 Receptor Agonists; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D018047:Receptors, Purinergic P1 / Q000502:physiology*; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D058906:Purinergic P1 Receptor Agonists; D058910:Purinergic P2 Receptor Agonists; D018047:Receptors, Purinergic P1; D018048:Receptors, Purinergic P2; D015762:2-Chloroadenosine; C005147:5'-adenylyl (beta,gamma-methylene)diphosphonate; D000255:Adenosine Triphosphate; D009638:Norepinephrine